Side effects
Vomiting on GLP-1 medication
How often vomiting was recorded in the trials behind semaglutide, tirzepatide and oral semaglutide, against placebo, and what those labels say to do about it.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.
Generated from the family's dataset. No clinician has reviewed this page as a document.
What it is
Vomiting is counted separately from nausea in every document cited below. A page about one is not a page about the other, and the rates are not the same.
Fluid loss is what the labels attach their warnings to here, rather than the vomiting itself.
How often it was reported
The figures below come from the trials the branded products were approved on, and each one is shown against the placebo arm of the same trial. They describe the people in those studies — not anyone on this program, and not the compounded preparations this program dispenses.
The prescribing information for Wegovy lists vomiting among the adverse reactions reported in the trials it was approved on. Measured in 24% of 2,116 adults taking 2.4 mg semaglutide weekly for 68 weeks, against 6% of 1,261 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-06-30
The prescribing information for Zepbound lists vomiting among the adverse reactions reported in the trials it was approved on. Measured in 13% of 941 adults taking 15 mg tirzepatide weekly for 72 weeks, against 2% of 958 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-09-02
The prescribing information for Rybelsus lists vomiting among the adverse reactions reported in the trials it was approved on. Measured in 8% of 356 adults with type 2 diabetes taking 14 mg oral semaglutide daily in placebo-controlled trials, against 3% of 362 adults with type 2 diabetes on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-08-19
What happens on this program
Your care team's refill check-in is where to raise this, and you can message them before it if you need to rather than waiting for the next one.
Nobody on this page can tell you whether to skip a dose. That is a prescribing decision, and it belongs to the clinician who wrote yours.
When to get help
Everything above reports what those documents themselves list. None of it is a judgement about what is happening to you: nobody who wrote this page has seen you, and reading a page is not a consultation.
If something is happening and you are not sure what it means, contact your provider or the pharmacy that dispensed to you. If it is severe, or you think it may be an emergency, call 911 or go to the nearest emergency room.
The prescribing information for Wegovy says nausea, vomiting and diarrhea can cause a loss of fluids, which may lead to kidney problems or make existing kidney problems worse, and directs a patient to tell a health care provider if they occur. DailyMed, U.S. National Library of Medicine, 2026-06-30
The prescribing information for Wegovy directs a patient to stop taking it and contact a health care provider promptly if severe abdominal pain that will not go away occurs, with or without vomiting, which it lists as a possible sign of inflammation of the pancreas. DailyMed, U.S. National Library of Medicine, 2026-06-30